Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DSC2
REST API REST API
Homo sapiens
DSC2 is differentially expressed in 282 experiments: 159 organism parts: prostate, tonsil, ... (157 more);, 174 disease states: normal, colon carcinoma, ... (172 more);, 98 cell types 467 cell lines 36 compound treatments and 74 other conditions.
Synonyms CDHF2, DSC3
Orthologs dsc2l (Danio rerio)   F1NJD7_CHICK (Gallus gallus)   DSC2 (Bos taurus)   Dsc2 (Mus musculus)   D3ZJR7_RAT (Rattus norvegicus)   dsc3 (Xenopus laevis)   O77704_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, cell-cell adherens junction, membrane, homophilic cell adhesion, cell junction, cell adhesion, integral to membrane, calcium ion binding, desmosome
InterPro Term Cadherin, Cadherin_cytoplasmic-dom, Desmo_cadherin, Cadherin_pro, Desmocollin
UniProt Accession A9X9L1, Q02487, Q68DY8, F8W7U2
Gene-Disease Assocation ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11
Search EB-eye ENSG00000134755
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
461 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, ... (50 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
cardiac myocyte
2
E-MTAB-25, E-AFMX-5
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
macrophage
2
E-GEOD-3982, E-GEOD-8286
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (60 experiments)

Factor Value U/D Experiments
gastric carcinoma
3
E-GEOD-15460, E-MTAB-37, E-GEOD-2685
colon carcinoma
1
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62, E-MTAB-57
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
168 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
none
5
6
E-GEOD-2803, E-GEOD-5741, E-GEOD-412, E-TABM-868, E-GEOD-5099, ... (11 experiments)
phoshate buffered saline
1
E-GEOD-3720
Ethanol
1
E-MEXP-2417
M-CSF
1
1
E-GEOD-5099
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
30 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
78
2
1
E-GEOD-21653
28
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-TABM-43, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-12773, E-MEXP-1446, E-TABM-440, E-MEXP-2146 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246, E-GEOD-20037

Replicate
studied in E-GEOD-10797, E-GEOD-19330

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-43, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922, ... (6 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.347 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM